BioArctic

BioArctic Receivables

The Accounts Receivable of BioArctic (BIOA B.ST) as of Oct 9, 2026 is 71.20 M SEK. In the previous year, Accounts Receivable was 223,000.00 SEK — a change of 31,826.46% (higher).

Receivables

71.20 MSEK

YoY

31,826.46%

Last updated:

Accounts Receivable of BioArctic is 2024 71.20 M SEK. Accounts Receivable of BioArctic was 2023 223,000.00 SEK. It decreases by 31,826.46% higher compared to the previous year.

The BioArctic Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2016
634,000.00 SEK
Jan 1, 2019
188,000.00 SEK
Jan 1, 2020
0.00 SEK
Jan 1, 2021
2.84 M SEK
Jan 1, 2022
0.00 SEK
Jan 1, 2023
223,000.00 SEK
Jan 1, 2024
71.20 M SEK
The BioArctic Receivables history
YEARReceivablesYoY
71.20 MSEK+31,826.46%
223,000.00SEK—
0.00SEK-100.00%
2.84 MSEK—
0.00SEK-100.00%
188,000.00SEK-70.35%
634,000.00SEK—
Access this data via the Eulerpool API
Get Free API Key

BioArctic Stock analysis

What does BioArctic do? BioArctic AB is a Swedish biotechnology company founded in 2003. The company is based in Stockholm and focuses on the development of innovative therapeutics for nervous system diseases such as Alzheimer's, Parkinson's, and spinal cord injuries. The company uses its expertise in biological and chemical drug research to discover and develop new therapeutic possibilities, with a focus on Amyloid-Beta production. BioArctic's business strategy is based on partnerships with pharmaceutical and biotech companies worldwide, working closely with partners to develop therapies and products that meet the needs and expectations of patients and doctors. BioArctic conducts research in three different areas: Alzheimer's, Parkinson's, and spinal cord injuries. The company works with partners such as Nutricia, Eisai, Just Biotherapeutics, Abcam, Neuropharm, AbbVie, Q-Med, Uppsala University, and the Karolinska Institute to develop treatments for these conditions. BioArctic has already brought several promising products to market, including BAN2401 for Alzheimer's and SC0806 for spinal cord injuries. Overall, BioArctic is a leading company in biological and chemical drug research, with a focus on developing new therapies and products for the benefit of patients and doctors worldwide. BioArctic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioArctic stock

Accounts Receivable of BioArctic is 71.20 M SEK in 2024.

Accounts Receivable of BioArctic changed from 223,000.00 SEK to 71.20 M SEK, representing a 31,826.46% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Accounts Receivable BioArctic since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's BioArctic historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — BioArctic

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — BioArctic